Literature DB >> 19330140

Optimal design for estimating parameters of the 4-parameter hill model.

Leonid A Khinkis1, Laurence Levasseur, Hélène Faessel, William R Greco.   

Abstract

Many drug concentration-effect relationships are described by nonlinear sigmoid models. The 4-parameter Hill model, which belongs to this class, is commonly used. An experimental design is essential to accurately estimate the parameters of the model. In this report we investigate properties of D-optimal designs. D-optimal designs minimize the volume of the confidence region for the parameter estimates or, equivalently, minimize the determinant of the variance-covariance matrix of the estimated parameters. It is assumed that the variance of the random error is proportional to some power of the response. To generate D-optimal designs one needs to assume the values of the parameters. Even when these preliminary guesses about the parameter values are appreciably different from the true values of the parameters, the D-optimal designs produce satisfactory results. This property of D-optimal designs is called robustness. It can be quantified by using D-efficiency. A five-point design consisting of four D-optimal points and an extra fifth point is introduced with the goals to increase robustness and to better characterize the middle part of the Hill curve. Four-point D-optimal designs are then compared to five-point designs and to log-spread designs, both theoretically and practically with laboratory experiments.D-optimal designs proved themselves to be practical and useful when the true underlying model is known, when good prior knowledge of parameters is available, and when experimental units are dear. The goal of this report is to give the practitioner a better understanding for D-optimal designs as a useful tool for the routine planning of laboratory experiments.

Keywords:  D-optimal design; Hill model; nonlinear model; parameter estimation

Year:  2003        PMID: 19330140      PMCID: PMC2656127          DOI: 10.1080/15401420390249925

Source DB:  PubMed          Journal:  Nonlinearity Biol Toxicol Med        ISSN: 1540-1421


  9 in total

1.  Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay.

Authors:  L M Levasseur; H Faessel; H K Slocum; W R Greco
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

2.  A comparison of methods for estimating individual pharmacokinetic parameters.

Authors:  T Amisaki; S Eguchi
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

3.  Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: application in pharmacokinetics.

Authors:  Y Merlé; F Mentré
Journal:  Math Biosci       Date:  1997-08       Impact factor: 2.144

4.  Fitting heteroscedastic regression models to individual pharmacokinetic data using standard statistical software.

Authors:  D M Giltinan; D Ruppert
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

5.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

6.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

Review 7.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

8.  Regression analysis, experimental error, and statistical criteria in the design and analysis of experiments for discrimination between rival kinetic models.

Authors:  B Mannervik
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

9.  Design of experiments for the precise estimation of dose-response parameters: the Hill equation.

Authors:  M Bezeau; L Endrenyi
Journal:  J Theor Biol       Date:  1986-12-21       Impact factor: 2.691

  9 in total
  11 in total

1.  An example of optimal phase II design for exposure response modelling.

Authors:  Alan Maloney; Marloes Schaddelee; Jan Freijer; Walter Krauwinkel; Marcel van Gelderen; Philippe Jacqmin; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-09-25       Impact factor: 2.745

2.  Quantitative high-throughput screening data analysis: challenges and recent advances.

Authors:  Keith R Shockley
Journal:  Drug Discov Today       Date:  2014-10-23       Impact factor: 7.851

3.  Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.

Authors:  Sneha V Gupta; Ellen J Sass; Melanie E Davis; Ryan B Edwards; Gerard Lozanski; Nyla A Heerema; Amy Lehman; Xiaoli Zhang; David Jarjoura; John C Byrd; Li Pan; Kenneth K Chan; A Douglas Kinghorn; Mitch A Phelps; Michael R Grever; David M Lucas
Journal:  AAPS J       Date:  2011-05-04       Impact factor: 4.009

4.  Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.

Authors:  Vincent H Tam; Amy N Schilling; Russell E Lewis; David A Melnick; Adam N Boucher
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Optimal designs based on the maximum quasi-likelihood estimator.

Authors:  Gang Shen; Seung Won Hyun; Weng Kee Wong
Journal:  J Stat Plan Inference       Date:  2016-07-15       Impact factor: 1.111

6.  Multiple-Objective Optimal Designs for Studying the Dose Response Function and Interesting Dose Levels.

Authors:  Seung Won Hyun; Weng Kee Wong
Journal:  Int J Biostat       Date:  2015-11       Impact factor: 0.968

7.  Evaluation of Drug Concentrations Delivered by Microiontophoresis.

Authors:  Douglas C Kirkpatrick; R Mark Wightman
Journal:  Anal Chem       Date:  2016-05-27       Impact factor: 6.986

8.  Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary.

Authors:  Lori L Tortorella; Nina H Pipalia; Sushmita Mukherjee; Ira Pastan; David Fitzgerald; Frederick R Maxfield
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

9.  Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.

Authors:  Erin Hertlein; Kyle A Beckwith; Gerard Lozanski; Timothy L Chen; William H Towns; Amy J Johnson; Amy Lehman; Amy S Ruppert; Brad Bolon; Leslie Andritsos; Arletta Lozanski; Laura Rassenti; Weiqiang Zhao; Tiina M Jarvinen; Leigha Senter; Carlo M Croce; David E Symer; Albert de la Chapelle; Nyla A Heerema; John C Byrd
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

10.  Temporal Data Set Reduction Based on D-Optimality for Quantitative FLIM-FRET Imaging.

Authors:  Travis Omer; Xavier Intes; Juergen Hahn
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.